High Sensitivity C-Reactive Protein Predictive Value for Cardiovascular Disease: A Nested Case Control from Isfahan Cohort Study (ICS).

Biomarkers / blood C-Reactive Protein / metabolism Cardiovascular Diseases / blood Case-Control Studies Follow-Up Studies Humans Incidence Iran / epidemiology Prognosis Risk Factors
Isfahan cohort study Odds ratio cardiovascular events high sensitivity C – reactive protein inflammation

Journal

Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391

Informations de publication

Date de publication:
06 02 2020
Historique:
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 14 4 2021
Statut: epublish

Résumé

High sensitivity C-reactive protein (hs-CRP) was proven to be an independent risk factor for cardiovascular diseases (CVDs). The aim of this study was to investigate the benefits of assessing hs-CRP among individuals with different cardiovascular risk factors. This nested case-control study was obtained from the Isfahan Cohort Study (ICS). Anyone who has been suffering from any CVDs, including myocardial infarction, unstable angina, sudden cardiac death and stroke was put in the case group. Density sampling method was utilized to choose the control group who had no aforementioned CVDs during follow-up. Four quartiles of hs-CRP (Q1: 0.1-2.3, Q2: 2.4-3, Q3: 3.1-4 and Q4: 4.1-14 mg/l) were assessed defining odds ratios (OR) of CVDs prediction in different CVDs risk factor categories. Confidence intervals of 95% are put in brackets. A total of 502 cases and 538 controls were recruited. All hs-CRP quartiles showed increased CVDs likelihood compared to normal subjects in terms of diabetes mellitus (DM) and hypertension (HTN). Second quartile showed a 1.93 [1.33-2.81] and 3.34 [1.36-8.17] increased risks in patients with hypertriglyceridemia or dyslipidemia, respectively. Smokers in the third quartile group revealed increased CVDs risk. The fourth quartile showed significant increased risks in patients suffering from hypercholesterolemia (OR = 1.91 [1.33-2.74]), high LDL-C (OR = 1.88 [1.33-2.66]), and hypertriglyceridemia (OR = 2.31 [1.57-3.41]). Our findings suggested that assessing hs-CRP is beneficial for predicting CVDs in patients with HTN and DM. Furthermore, specific patients with lipid abnormalities or history of smoking benefits from checking hs-CRP.

Sections du résumé

Background
High sensitivity C-reactive protein (hs-CRP) was proven to be an independent risk factor for cardiovascular diseases (CVDs). The aim of this study was to investigate the benefits of assessing hs-CRP among individuals with different cardiovascular risk factors.
Methods
This nested case-control study was obtained from the Isfahan Cohort Study (ICS). Anyone who has been suffering from any CVDs, including myocardial infarction, unstable angina, sudden cardiac death and stroke was put in the case group. Density sampling method was utilized to choose the control group who had no aforementioned CVDs during follow-up. Four quartiles of hs-CRP (Q1: 0.1-2.3, Q2: 2.4-3, Q3: 3.1-4 and Q4: 4.1-14 mg/l) were assessed defining odds ratios (OR) of CVDs prediction in different CVDs risk factor categories. Confidence intervals of 95% are put in brackets.
Results
A total of 502 cases and 538 controls were recruited. All hs-CRP quartiles showed increased CVDs likelihood compared to normal subjects in terms of diabetes mellitus (DM) and hypertension (HTN). Second quartile showed a 1.93 [1.33-2.81] and 3.34 [1.36-8.17] increased risks in patients with hypertriglyceridemia or dyslipidemia, respectively. Smokers in the third quartile group revealed increased CVDs risk. The fourth quartile showed significant increased risks in patients suffering from hypercholesterolemia (OR = 1.91 [1.33-2.74]), high LDL-C (OR = 1.88 [1.33-2.66]), and hypertriglyceridemia (OR = 2.31 [1.57-3.41]).
Conclusions
Our findings suggested that assessing hs-CRP is beneficial for predicting CVDs in patients with HTN and DM. Furthermore, specific patients with lipid abnormalities or history of smoking benefits from checking hs-CRP.

Identifiants

DOI: 10.5334/gh.367 PMID: 32489776 PMC: PMC7218777
pubmed: 32489776
doi: 10.5334/gh.367
pmc: PMC7218777
doi:

Substances chimiques

Biomarkers 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3

Informations de copyright

Copyright: © 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Références

Diabetes Metab Res Rev. 2013 Jul;29(5):398-405
pubmed: 23463453
ARYA Atheroscler. 2016 May;12(3):132-137
pubmed: 27752270
Clin Exp Hypertens. 2014;36(5):302-8
pubmed: 23848297
BMC Public Health. 2010 Sep 28;10:579
pubmed: 20875142
PLoS One. 2013 Dec 11;8(12):e81597
pubmed: 24349092
PLoS One. 2015 Aug 17;10(8):e0135713
pubmed: 26280165
BMJ Open. 2011 May 26;1(1):e000126
pubmed: 22021769
PLoS One. 2013 Dec 03;8(12):e81778
pubmed: 24312587
Am J Epidemiol. 2013 Oct 1;178(7):1076-84
pubmed: 24026395
Adv Biomed Res. 2014 Nov 29;3:242
pubmed: 25538928
Clin Exp Hypertens. 2008 Jul;30(5):367-74
pubmed: 18633759
J Am Heart Assoc. 2017 Aug 23;6(8):
pubmed: 28838917
Diabetes Res Clin Pract. 2014 Dec;106(3):597-604
pubmed: 25312870
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Curr Opin Cardiol. 2006 Jan;21(1):1-6
pubmed: 16355022
Am J Cardiol. 2012 Nov 15;110(10):1464-7
pubmed: 22858184
J Clin Lab Anal. 2016 Sep;30(5):672-6
pubmed: 26857805
ARYA Atheroscler. 2012 Summer;8(2):70-5
pubmed: 23056106
ARYA Atheroscler. 2018 Jul;14(4):163-168
pubmed: 30627192
Lancet. 1997 May 3;349(9061):1269-76
pubmed: 9142060
JAMA. 2003 Aug 20;290(7):898-904
pubmed: 12928466
N Engl J Med. 2004 Dec 16;351(25):2599-610
pubmed: 15602020
Int J Epidemiol. 2002 Dec;31(6):1117-22; author reply 1134-5
pubmed: 12540704
Int J Environ Res Public Health. 2016 Aug 31;13(9):
pubmed: 27589783
J Hum Hypertens. 2011 Sep;25(9):545-53
pubmed: 21107436
BMC Public Health. 2015 Dec 29;15:1313
pubmed: 26715355
Circulation. 2004 Mar 23;109(11):1349-53
pubmed: 15023871
Obes Res Clin Pract. 2013 Jul-Aug;7(4):e297-300
pubmed: 24306158
Ann Clin Biochem. 2013 Sep;50(Pt 5):457-64
pubmed: 23880621
Thromb Res. 2007;119(1):79-84
pubmed: 16476470
Eur Heart J. 2006 Jul;27(13):1610-9
pubmed: 16495286
Clin Med Insights Cardiol. 2015 Jan 07;8(Suppl 3):13-21
pubmed: 25674025
Endocr J. 2008 Aug;55(4):717-22
pubmed: 18493107
Circulation. 2004 Jun 29;109(25 Suppl 1):IV6-19
pubmed: 15226246
Am J Med Sci. 2009 Dec;338(6):440-6
pubmed: 20010154
Circ J. 2004 Apr;68(4):297-303
pubmed: 15056824
N Engl J Med. 2002 Nov 14;347(20):1557-65
pubmed: 12432042
Circulation. 2004 Feb 24;109(7):837-42
pubmed: 14757686

Auteurs

Pooya Koosha (P)

Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR.

Hamidreza Roohafza (H)

Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, IR.

Nizal Sarrafzadegan (N)

Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR.

Mehrbod Vakhshoori (M)

Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR.

Mohammad Talaei (M)

Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR.
Institute of Population Health Sciences, Barts and the London School of Medicine, Queen Mary University of London, GB.

Erfan Sheikhbahaei (E)

Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR.

Masoumeh Sadeghi (M)

Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IR.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du sang › Immunoprotéines › Protéine C-réactive › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Maladies cardiovasculaires › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Régions géographiques › Asie › Asie de l'Ouest › Moyen Orient › Iran › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Diagnostic › Pronostic › High Sensitivity C-Reactive Protein Predictive...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › High Sensitivity C-Reactive Protein Predictive...